Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction according to body weight

Heart Failure

Real-life implementation of guideline-recommended medical therapy in heart failure with reduced ejection fraction: Effects on prognosis and left ventricular ejection fraction. Primary results of TITRATE-HF

Eur J Heart Fail

Malgie J, Wilde MI, Koudstaal S, Denham R, da Fonseca CA, Swart HP, van Ofwegen CEE, Yilmaz A, Pisters R, Linssen GCM, Faber N, van Heerebeek L, van de Swaluw JEC, de Boer RA, Brunner-La Rocca HP, Brugts JJ

doi: 10.1002/ejhf.70006

Heart Failure

Cardiac rhythm devices in heart failure with reduced ejection fraction - role, timing, and optimal use in contemporary practice. European Journal of Heart Failure expert consensus document

Eur J Heart Fail

Bozkurt B, Mullens W, Leclercq C, Russo AM, Savarese G, Böhm M, Hill L, Kinugawa K, Sato N, Abraham WT, Bayes-Genis A, Mebazaa A, Rosano GMC, Zieroth S, Linde C, Butler J

doi: 10.1002/ejhf.3641

Heart Failure

Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection Fraction

JACC Heart Fail

Siqueira SRO, Pabon MA, Vaduganathan M, Claggett BL, Lam CSP, Kosiborod MN, de Boer RA, Shah SJ, Fang JC, Desai AS, Jhund PS, Inzucchi SE, Martinez F, Hernandez AF, Petersson M, McMurray JJV, Solomon SD, Vardeny O

doi: 10.1016/j.jchf.2025.102585

Heart Failure

Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF

Circ Heart Fail

Butt JH, Henderson AD, Jhund PS, Claggett BL, Desai AS, Borentain M, Rohwedder K, Dayoub R, De Sanctis Y, Lam CSP, Senni M, Shah SJ, Voors AA, Bauersachs J, Fonseca C, Linssen GCM, Petrie MC, Schou M, Verma S, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV

doi: 10.1161/CIRCHEARTFAILURE.125.013201

Heart Failure

Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial

Eur J Heart Fail

Butt JH, Jhund PS, Henderson AD, Claggett BL, Desai AS, Lam CSP, Mueller K, Scheerer MF, Viswanathan P, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV

doi: 10.1002/ejhf.3661

Heart Failure

Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial

Eur Heart J

Butler J, Fioretti F, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Teixeira PP, Ezekowitz JA, Gates D, Lam CSP, Lewis EF, Lindenfeld J, Mentz RJ, O'Connor CM, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Zannad F

doi: 10.1093/eurheartj/ehaf655

Heart Failure

One-Year Outcomes in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction Prescribed Quadruple Medical Therapy at Discharge

JAMA Cardiol

Greene SJ, Xu H, Chiswell K, Felker GM, Lewsey SC, Divanji PH, Goertz HP, Heitner SB, Shreay S, Pandey A, Yancy CW, Butler J, Fonarow GC

doi: 10.1001/jamacardio.2025.5339

Heart Failure

Blood pressure, safety and clinical efficacy of vericiguat in chronic heart failure with reduced ejection fraction: Insights from the VICTOR trial

Eur J Heart Fail

Mentz RJ, Butler J, McMullan CJ, Wojdyla DM, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Ezekowitz JA, Gates D, Lam CSP, Lewis EF, Lindenfeld J, O'Connor CM, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, Teixeira PP, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Zannad F, VICTOR Study Group

doi: 10.1002/ejhf.70033

Heart Failure

Heart Failure With Preserved Ejection Fraction Across the Spectrum of Body Mass Index: Hemodynamic and Echocardiographic Characteristics and Outcomes

JACC Heart Fail

Harrington J, Giczewska A, Rao VN, Fudim M, Peters AE, Chrischilles E, Jones WS, May H, Steinberg BA, VanWormer J, Cyr DD, Felker GM

doi: 10.1016/j.jchf.2025.102768

Related content

Real-life implementation of guideline-recommended medical therapy in heart failure with reduced ejection fraction: Effects on prognosis and left ventricular ejection fraction. Primary results of TITRATE-HF

Cardiac rhythm devices in heart failure with reduced ejection fraction - role, timing, and optimal use in contemporary practice. European Journal of Heart Failure expert consensus document

Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection Fraction

Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF

Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial

Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial

One-Year Outcomes in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction Prescribed Quadruple Medical Therapy at Discharge

Blood pressure, safety and clinical efficacy of vericiguat in chronic heart failure with reduced ejection fraction: Insights from the VICTOR trial

Heart Failure With Preserved Ejection Fraction Across the Spectrum of Body Mass Index: Hemodynamic and Echocardiographic Characteristics and Outcomes